

SYNTHESIS AND CALCIUM CHANNEL ANTAGONIST ACTIVITY OF NIFEDIPINE ANALOGUES WITH CHLOROINDOLYL SUBSTITUENT

ABBAS SHAFIEE*, AHMAD-REZA DEHPOUR**, FARZIN HADIZADEH* and BAGHER REZAEI*

*Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

**Department of Pharmacology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Various diester analogues of nifedipine in which the ortho nitrophenyl group at position 4 were replaced by 3-chloro-1H-2-indolyl substituent, were synthesized and evaluated as calcium antagonists on guinea-pig ileal smooth muscle. Nifedipine was used as a standard. Compound 6f was found to be the most active.

Key words: Calcium channel blockers; Dihydropyridine, Nifedipine analogues.

INTRODUCTION

Very soon after the discovery of the cardiovascular properties of 1,4-dihydropyridines, it was found that these substances act by inhibiting the entry of Ca^{2+} into the cells of cardiac and vascular muscle through the voltage-dependent calcium channels (1).

Structurally diverse groups of compounds are known to be effective as calcium antagonists (2). The most potent class of antagonists comprises derivatives of 1,4-dihydropyridine of which the most widely known agent is nifedipine (3). This class of compounds have been the subject of many structure-activity relationship studies (4-6). Previously we reported the effect of C-4 nitroimidazolyl and methylsulfonylimidazolyl substituents in conjunction with various C-3, C-5 diesters on calcium channel antagonist activities (7, 8). This paper describes the synthesis and activity of 1,4-dihydro-2,6-dimethyl-4-(3-chloro-1H-2-indolyl)-3,5-pyridine-dicarboxylic acid esters.

MATERIALS AND METHODS

Melting points were determined on a Kofler hot stage apparatus and are uncorrected. 1H -NMR spectra were run on a Varian 400 Unity plus or a Bruker FT-80 spectrometer. Tetramethylsilane was used as an internal standard. Mass spectra were measured with a Finnigan TSQ-70 spectrometer at 70 eV. The IR spectra were obtained using a Nicolet FT-IR Magna 550. All

compounds gave satisfactory elemental analyses within $\pm 0.4\%$ of the theoretical values.

Dimethyl 1,4-Dihydro-2,6-dimethyl-4-(3-chloro-1H-2-indolyl)-3,5-pyridinedicarboxylate (3a).

A solution of ammonium hydroxide (25%, 0.4 ml) was added to a stirring solution of compound 2 (0.268 g, 1.5 mmol) and methyl 3-oxobutanoate 1 (0.371 g, 3.2 mmol) in absolute ethanol (8 ml). The mixture was protected from light and heated overnight under reflux. After cooling the reaction, ethanol was removed and the residue purified by thin layer chromatography (petroleum ether-ethylacetate; 75:25) to give 0.31 g, (55%) of 3a, mp 230-232°C (CCl₄/hexane); IR (KBr): ν (cm⁻¹) 3420 (NH), 3340 (NH), 1700 (C=O); 1H -NMR (CDCl₃): δ 8.29 (brs, 1H, NH indole), 7.50 (d, J=8Hz, 1H, H₇ indole), 7.24 (d, J=8Hz, 1H, H₄ indole), 7.14 (t, J=8Hz, H₅ indole) 7.09 (t, J=8 Hz, H₃ indole), 5.77 (brs, 1H, NH), 5.33 (s, 1H, H₄-dihydropyridine), 3.66 (s, 6H, 2COOMe), 2.34 (s, 6H, 2Me); ^{13}C (CDCl₃) δ 167.89 (CO), 145.12(C₈), 138.08 (C₉) 133.64 (C₂, indole), 126.45 (C₃, indole) 122.31 (C₆, indole), 119.81 (C₄, indole), 117.71 (C₅, indole), 110.9 (C₇), 100.24 (C₂ and C₆, dihydropyridine), 96.12 (C₃ and C₅ dihydropyridine), 51.24 (OMe), 33.04 (C₄, dihydropyridine), 19.53 (C₂ and C₆, methyl); MS: m/z (%) 374 (M⁺, 18), 339 (62), 307 (22), 224 (100), 192 (12), 59 (8). Other

compounds of the table 1 (3b-e) were prepared similarly.

Methyl 2-[(3-Chloro-1H-2-indolyl)methylene]-3-oxobutanoate (4, R₁=methyl, n=0): A mixture of compound 2 (268 mg, 1.5 mmol), methyl 3-oxobutanoate 1 (174 mg, 1.5 mmol), glacial acetic acid (0.12 ml), piperidine (0.04 ml), anhydrous magnesium sulfate (360 mg, 3 mmol) and dry chloroform (20 ml) was refluxed for 2 h. The reaction mixture was filtered and the chloroform was removed. The oily residue was purified by thin layer chromatography (petroleum ether-ethyl acetate; 75:25) to give 375 mg (90%) of 4, mp 117-118°C (methanol); IR (KBr): $\nu(\text{cm}^{-1})$, 1700; ¹H-NMR (CDCl₃): δ 10.84 (brs, 1H, NH indole), 8.02 (s, 1H, CH=C), 7.63 (m, 1H, arom), 7.25 (m, 3H, arom), 3.91 (s, 3H, CH₃O), 2.58 (s, 3H, CH₃).

3-Methyl,5-isopropyl 1,4-Dihydro-2,6-dimethyl-4-(3-chloro-1H-2-indolyl)-3, 5-pyridinedicarboxylate (6b): To a stirring solution of compound 4 (R₁=methyl, n=0, 277 mg, 1 mmol) in absolute ethanol (8 ml), was added isopropyl aminocrotonate 5 (R₂=CH(CH₃)₂, 143 mg, 1 mmol). The solution was protected from light and refluxed overnight. After cooling, ethanol was removed and the residue was purified by thin layer chromatography (petroleum ether-ethyl acetate; 75:25) to give 245 mg (61%) of 6b, mp 209-210°C (CCl₄/hexane). IR (KBr): $\nu(\text{cm}^{-1})$, 3400, 3300 (NH), 1670 (CO); ¹H-NMR (CDCl₃): δ 8.29 (brs, 1H, NH indole), 7.48 (d, J=8Hz, 1H, H₇ indole), 7.24 (d, J=8Hz, 1H, H₄ indole), 7.14 (t, J=8Hz, 1H, H₅ indole), 7.09 (t, J=8Hz, H₃ indole), 5.77 (brs, 1H, NH), 5.33(s, 1H, H₄-dihydropyridine), 4.98[m, 1H, CHMe₂], 3.66 (s, 3H, COOMe), 2.34 (s, 6H, 2CH₃), 1.19 and 1.23 [d,d J=7.5 Hz, 6H, (CH₃)₂CH], ¹³C(CDCl₃): δ 167.89 and 166.97 (CO), 145.14 (C₈), 138.26 (C₉), 133.56 (C₂, indole), 126.44 (C₃, indole), 122.27 (C₆, indole), 119.74 (C₄, indole), 117.68 (C₅, indole), 110.83 (C₇), 100.83 (C₂ and C₆, dihydropyridine), 95.85 (C₃ and C₅, dihydropyridine), 67.57 [-CHOCO], 51.14 (OMe), 32.99 (C₄, dihydropyridine), 22.13 and 21.93[-(CH)Me₂], 19.65 (C₂ and C₆-methyl); MS: m/z (%) 402 (M⁺, 35), 367 (100), 329 (5), 210 (88).

Other compounds 6a-k were prepared similarly.

Pharmacology: Male albino guinea-pigs (300-450 g) were killed by a blow on the head. The

intestine was removed above the ileocaecal junction and longitudinal smooth muscle segments of 2 cm length were mounted under a resting tension of 0.5 g. The segments were maintained at 37°C in a 20-ml jacketed organ bath containing oxygenated physiological saline solution of the following millimolar composition: NaCl, 137; CaCl₂, 1.8; KCl, 2.7; MgSO₄, 1.1; NaH₂PO₄, 0.4; NaHCO₃, 12 and glucose, 5. The muscles were equilibrated for 1 h with a solution which change was every 15 min. The contractions were recorded with a force displacement transducer (F-50) on a NARCO physiograph. Test agents were prepared as 10⁻² M stock solutions in ethanol and stored protected from light. Dilutions were made into double distilled water. The contractile response was taken as the 100% value for the tonic (slow) component of the response. The contraction was elicited with 80 mM KCl. Test compounds were cumulatively added after the dose response for KCl was determined. Test compound-induced relaxation of contracted muscle was expressed as percent of control. The IC₅₀ values (concentration needed to produce 50% relaxation on contracted ileal smooth muscle) were graphically determined from the concentration-response curves (9,10).


RESULTS AND DISCUSSION

Chemistry: Symmetrical 3a-e and asymmetrical 6a-k analogues of nifedipine were synthesized according to scheme 1. The symmetrical analogues 3a-e were prepared by classical Hantzsch condensation (11) in which 3-chloro-1H-indol-2-carboxaldehyde 2 (12) was reacted with 3-oxobutanoic acid esters 1 (13) and ammonium hydroxide. The asymmetrical analogues 6a-k were synthesized by a procedure reported previously (14).

Pharmacology: The calcium channel antagonist activities (IC₅₀) of compounds 3a-e and 6a-k were determined as the concentration needed to produces 50% relaxation of contracted guinea-pig ileal longitudinal smooth muscle (9). The results are summarized in tables 1 and 2. A comparison of the activities of symmetrical esters 3a-e, indicate that increasing the size of the ester group increases activity 3c>3a.

In asymmetrical series of phenylalkyl esters when R₂ is a small substituent (R₂=CH₃) increasing the length of methylene chain


Table 1: Physical properties and calcium channel antagonist activities of symmetrical esters 3a-e



Compound	R	n	Mp(°C)	Yield (%)	IC ₅₀ ^a (M)
3a	CH ₃	0	230-232	55	2.43 (0.33) × 10 ⁻⁸
3b	CH ₃	1	213-215	44	4.32(0.46) × 10 ⁻⁸
3c	C(CH ₃) ₃	0	241-243	65	6.35 (0.48) × 10 ⁻⁹
3d	C ₆ H ₅	1	165-166	51	8.29 (0.43) × 10 ⁻⁹
3e	C ₆ H ₅	4	120-121	47	1.77 (0.87) × 10 ⁻⁷
nifedipine					2.75 (0.36) × 10 ⁻¹⁰


a; n=6, Standard deviation in parentheses.

Table 2: Physical properties and calcium channel antagonist activities of asymmetrical esters 6a-k



Compound	R ₁	n	R ₂	Mp(°C)	Yield (%)	IC ₅₀ ^a (M)
6a	CH ₃	1	CH ₃	168-169	45	1.46(0.64) × 10 ⁻⁸
6b	CH(CH ₃) ₂	0	CH ₃	209-210	61	2.01 (0.45) × 10 ⁻⁸
6c	CH(CH ₃) ₂	0	C ₂ H ₅	256-257	55	1.17 (0.30) × 10 ⁻⁸
6d	C(CH ₃) ₃	0	CH ₃	220-221	57	9.02 (0.50) × 10 ⁻⁹
6e	C(CH ₃) ₃	0	C ₂ H ₅	222-224	52	6.14 (0.41) × 10 ⁻⁹
6f	C ₆ H ₅	1	CH ₃	170-171	62	1.13 (0.36) × 10 ⁻⁹
6g	C ₆ H ₅	1	C ₂ H ₅	95-96	54	2.56 (0.35) × 10 ⁻⁹
6h	C ₆ H ₅	2	CH ₃	125-126	65	3.51 (0.26) × 10 ⁻⁹
6i	C ₆ H ₅	2	C ₂ H ₅	79-80	55	4.51 (0.56) × 10 ⁻⁹
6j	C ₆ H ₅	4	CH ₃	147-148	40	6.72 (0.34) × 10 ⁻⁹
6k	C ₆ H ₅	4	C ₂ H ₅	143-144	46	8.24 (0.30) × 10 ⁻⁹
nifedipine						2.75 (0.36) × 10 ⁻¹⁰

a; n=6, Standard deviation in parentheses.



Scheme 1

decreased activity (**6j**<**6h**<**6f**). Comparison of the effect of phenyl relative to alkyl substituent, shows that phenyl derivatives are more active than alkyl derivatives. Compound **6f** ($R_1=C_6H_5$, $R_2=CH_3$, $n=1$) was the most active compound.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Research Council of Tehran University of Medical Sciences.

REFERENCES

1. Fleckenstein, A., Tritthart, H., Doring, H.J. and Byon, K.Y. (1972), Bay a 1040, a highly potent Ca^{++} antagonistic inhibitor of electromechanical coupling processes in mammalian myocardium. *Arzneim.* 22:22-23.
2. Goldmann, S. and Stoltefuss, J. (1991), 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities. *Angew Chem. Int. Ed. Engl.* 30: 1559-1578.
3. Fleckenstein, A. (1977), Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. *Annu. Rev. Pharmacol. Toxicol.* 17:149-166.
4. Langs, D. A., Strong, P.D. and Triggle, D.J. (1990), Receptro model for the molecular basis of tissue selectivity of 1,4-dihydropyridine calcium channel drugs. *J. Comput. Aided Mol. Des.* 4: 215-230.
5. Mager, P.P., Coburn, R. A., Solo, A. J., Triggle, D.J. and Rothe, H. (1992), QSAR, Diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium channel antagonists: a difficult road ahead. *Drug Des. Discov.* 8: 273-289.
6. Rovnyak, G.C., Kimbal, S.D., Beyer, B., Cucinotta, G., DiMarco, J.D., Gougoutas, J., Hedberg, A., Malley, M., McCarthy, J.P., Zhang, R. and Moreland, S. (1995), Calcium entry blockers and

- activators: conformational and structural determinations of dihydropyridine calcium channel modulators. *J. Med. Chem.* 38: 119-129.
7. Shafiee, A., Miri, R., Dehpour, A.R. and Soleymani, F. (1996), Synthesis and calcium channel antagonist-activity of nifedipine analogues containing nitroimidazolyl substituent. *Pharm. Sci.* 2: 541-543.
 8. Shafiee, A., Dehpour, A.R., Hadizadeh, F. and Azimi, M. (1998), Synthesis and calcium channel antagonist activity of nifedipine analogues with methyl- sulfonylimidazolyl substituent. *Pharmaceutica Acta Helvetiae* 73: 75-79.
 9. Bolger, G.T., Gengo, P., Klochowksi, R., Luchowski, E., Siegel, H., Janis, R.A., Triggle, A.M. and Triggle, D.J. (1983), Characterization of binding of the Ca^{2+} channel antagonist, [3H] nitrendipine to guinea-pig. *J. Pharm. Exp. Ther.* 225: 291-309.
 10. Rovnyak, G.C., Atwal, K.S., Hedberg, A., Kimbal, S.D., Moreland, S., Gougoutas, J.Z., O'Reilly, B.C., Schwartz, J. and Malley, M.F. (1992), Dihydropyridine calcium channel blockers: 4. Basic 3-substituted-4-aryl-1,4-dihydropyridine-5-carboxylic acid esters potent antihypertensive agents. *J. Med. Chem.* 35: 3236-3254.
 11. Hantzsch, A. (1882), Ueber die synthese pyridinartiger verbindungen aus acetessigather und aldehydammoniak. *Justus Liebigs Ann. Chem.* 215:1-82.
 12. Majo, V.J. and Perumal, P.T. (1996), One-pot synthesis of heterocyclic β - chlorovinyl aldehydes using Vilsmeier reagent. *J. Org. Chem.* 61: 6523- 6525.
 13. Clemens, R.J. and Hyatt, H.A. (1985), Acetoacetylation with 2,2,6-trimethyl-4H-1,3-dioxine-4-one: a convenient alternative to diketene. *J. Org. Chem.* 50: 2431-2435.
 14. Meyer, H., Bossert, F., Wehinger, E., Stoepel, K. and Voter, W. (1981), Synthese und vergleichende pharmakologische untersuchungen von 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-carbonsaureestern mit nicht-identischen esterfunktionen. *Arzneim. Forsch.* 31: 407-409.